[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332725-105":59,"doc-detail-332725-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-effect-of-glp-1r-agonists-on-the-medical-triad-of-obesity-diabetes-and-cancer","The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer","","Glucagon-like peptide-1 receptor (GLP-1R) agonists have attracted major interest for their therapeutic value in the interconnected conditions of diabetes, obesity, and cancer. The review describes GLP-1R functions in type 2 diabetes mellitus, including glucose homeostasis, β-cell proliferation, and insulin release, and summarizes benefits in obesity via appetite reduction, intake moderation, and weight regulation. It further highlights multi-pathway influences on cancer progression, while noting gaps in in vivo data for specific agents and the need to clarify semaglutide-related mechanisms and cancer risk.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-effect-of-glp-1r-agonists-on-the-medical-triad-of-obesity-diabetes-and-cancer/332725/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-effect-of-glp-1r-agonists-on-the-medical-triad-of-obesity-diabetes-and-cancer/332725.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What conditions are addressed by GLP-1R agonists in this review?","Question",{"text":112,"@type":113},"The review focuses on the medical triad connecting obesity, type 2 diabetes, and cancer progression risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does GLP-1R relate to type 2 diabetes mellitus according to the abstract?",{"text":117,"@type":113},"GLP-1R is described as supporting glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does the review emphasize the need for further research on specific GLP-1R agonists like semaglutide?",{"text":121,"@type":113},"It states that current literature lacks in vivo studies on specific agents, and that the mechanisms and cancer risk associations—despite some promising outcomes—require deeper investigation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},332725,1790183982,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer and Metastasis Reviews (2024) 43:1297–1314 [https://doi.org/10.1007/s10555-024-10192-9](https://doi.org/10.1007/s10555-024-10192-9)  \nThe effect of GLP‑1R agonists on the medical triad of obesity, diabetes, and cancer  \nShahad Sabaawi Ibrahim1 · Raghad Sabaawi Ibrahim1 · Batoul Arabi1 · Aranka Brockmueller2 · Mehdi Shakibaei2 · Dietrich Büsselberg1  \nReceived: 1 January 2024 / Accepted: 21 May 2024 / Published online: 27 May 2024 © The Author(s) 2024  \nAbstract  \nGlucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.  \nKeywords Ozempic · Semaglutide · Cancer · Diabetes · Obesity · GLP1RA  \n1 Introduction  \nSemaglutide (US brand name Ozempic or Wegovy), a Glucagon-like peptide-1 receptor (GLP-1R) agonist containing the active ingredient semaglutide, is approved by the Food and Drug Administration for its potential therapeutic role in obesity and diabetes mellitus (DM) similar to other agonists within the GLP-1R family such as liraglutide. It not only successfully regulates blood sugar levels [1] but also reduces the appetite and, thereby, the weight of patients [2], especially in individuals  \nShahad Sabaawi Ibrahim and Raghad Sabaawi Ibrahim contributed equally to this work.  \n* Dietrich Büsselberg [dib2015@qatar-med.cornell.edu](dib2015@qatar-med.cornell.edu)  \n1 Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha 24144, Qatar  \n2 Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Pettenkoferstr. 11, D-80336 Munich, Germany  \nwith obesity and type 2 diabetes mellitus (T2DM) . But why is there even a need for such a medication? And are potential long-term consequences, such as promoting the development or spread of cancer, receiving sufficient attention?  \nThe number of overweight people has been increasing rapidly in recent years due to genetic, socio-economic, lifestyle, and cultural influences. Compared to the past, this not only affects adults but also numerous children and young people. Especially in American and European regions, at least 50% of residents now weigh more than the international standardized body mass index (BMI) recommends [3] . In this relation, a BMI of 30 kg/m2 or higher is classified as obese [4], whose causes lie in excessive calorie intake or reduced energy expenditure, and modern lifestyles promote both a lack of exercise and an unhealthy diet. Therefore, both these lifestyle factors and obesity itself represent a significant risk factor for metabolic disease T2DM [3, 5] .  \nDM is one of the most common metabolic diseases worldwide, with around 530 million people currently affected and an estimated 1.3 billio","cbCaijvjVCtqKYrl","https://ap.wps.com/l/cbCaijvjVCtqKYrl","pdf",1393502,18,"English","# Abstract\n# Keywords\n# 1 Introduction\n# 2 The medical triad","[{\"question\":\"What conditions are addressed by GLP-1R agonists in this review?\",\"answer\":\"The review focuses on the medical triad connecting obesity, type 2 diabetes, and cancer progression risk.\"},{\"question\":\"How does GLP-1R relate to type 2 diabetes mellitus according to the abstract?\",\"answer\":\"GLP-1R is described as supporting glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release.\"},{\"question\":\"Why does the review emphasize the need for further research on specific GLP-1R agonists like semaglutide?\",\"answer\":\"It states that current literature lacks in vivo studies on specific agents, and that the mechanisms and cancer risk associations—despite some promising outcomes—require deeper investigation.\"}]","The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer | PDF",1789999212,45]